Gavo-Cel Granted Orphan Drug Designation for Cholangiocarcinoma

Article

The investigational cell therapy consists of T-cell receptor (TCR) fusion construct T cells (TRuC-T cells).

This content originally appeared on our sister site, OncLive.

Gavocabtagene autoleucel (gavo-cel; TC-210; TCR2 Therapeutics) has received orphan drug designation as a potential treatment of cholangiocarcinoma.1

Gavo-cel is a novel, autologous cell therapy defined as T-cell receptor (TCR) fusion construct T cells (TRuC-T cells). It is currently being evaluated in a phase 1/2 trial (NCT03907852) in treatment-refractory mesothelin-expressing solid tumors. Findings from the study, which will comprise data from patients with malignant mesothelioma, ovarian cancer, and cholangiocarcinoma, will be presented at the 2021 ESMO Congress.

Mesothelin is described as a cell-surface glycoprotein highly expressed in several solid malignancies, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, and pancreatic cancer. Moreover, mesothelin overexpression is linked with worse prognosis in select tumors; it has an active role in malignant transformation and tumor aggressiveness via promotion of cancer cell proliferation, invasion, and metastasis.

Non–small cell lung cancers (NSCLCs), ovarian cancers, mesotheliomas and cholangiocarcinomas that express mesothelin comprise 80,000 patients in the United States each year.

READ MORE: First Patient Dosed in Trial of GEN-011 for Treating Solid Tumors

Gavo-cel is described as autologous genetically engineered T cells that express a single-domain antibody with the ability to recognize human mesothelin that is fused to CD3-epsilon subunit; this is incorporated into the endogenous T-cell receptor complex.

Preclinical data showed that TRuC-T cells demonstrated encouraging activity compared with CAR T-cell therapy, while secreting lower levels of cytokine release.

In the ongoing, phase 1/2 trial, investigators sought to determine the recommended phase 2 dose (RP2D) of gavo-cel (phase 1 portion) as well as the overall response rate (ORR; phase 2) in approximately 70 patients with advanced mesothelin-expressing, unresectable, metastatic, or recurrent cancers.2 As part of a lymphodepletion regimen, fludarabine will be administered at 30 mg/m2 daily on days -7 through -4 and cyclophosphamide at 600 mg/m2 daily on days -6 through -4 followed by gavo-cel.

To be eligible for enrollment, patients aged 18 years or older must have a confirmed diagnosis of malignant pleural/peritoneal mesothelioma, serous ovarian adenocarcinoma, cholangiocarcinoma, or NSCLC; have mesothelin expression on more than 50% of tumor cells that are immunohistochemistry 2+ and/or 3+; must have received at least 1 systemic standard treatment for metastatic or unresectable disease; an ECOG performance status of 0 or 1; a left ventricular ejection fraction greater than 45%; fit for leukapheresis and has adequate venous access for cell collection; and must have adequate organ function.

In December 2020, TCR2 Therapeutics announced interim findings from the phase 1 portion of the trial.3 As of the data cutoff date of November 24, 2020, which had data from the first 8 patients, results showed that there were 3 partial responses (PRs) via RECIST v1.1 criteria. The first patient with ovarian cancer on study achieved a confirmed PR up until 6 months.

Additional data showed that the first patient who received gavo-cel at a higher dose, 1 x 108/m2, without lymphodepletion had stable disease for 2 months and did not experience significant toxicities. There were also reports of TRuC-T cell expansion and cytokine induction in all patients.

Regarding safety, 2 patients as of the data cutoff data reported treatment-related non-hematologic toxicities that were higher than grade 2; there was no evidence of neurotoxicity nor on-target/off-tumor toxicity.

TC-110, another TRuC-T cell product, is being studied in an ongoing phase 1/2 trial of adult patients with CD19-positive acute lymphoblastic leukemia and with aggressive or indolent non-Hodgkin lymphoma.

REFERENCES
1. TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma. News release. TCR2 Therapeutics. September 2, 2021. Accessed September 2, 2021. https://bit.ly/2V8GibVA
2. Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer. ClinicalTrials.gov. Updated June 29, 2021. Accessed September 2, 2021. https://clinicaltrials.gov/ct2/show/NCT03907852
3. TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of Tc-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors. News release. TCR2 Therapeutics. December 13, 2020. Accessed September 2, 2021. https://bit.ly/2WHdV58
Related Videos
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
Amar Kelkar, MD, a stem cell transplantation physician at the Dana-Farber Cancer Institute
David Porter, MD
N. Nora Bennani, MD
Rebecca Epperly, MD, a clinical investigator in the Department of Bone Marrow Transplantation & Cellular Therapy at St. Jude Children’s Research Hospital
© 2024 MJH Life Sciences

All rights reserved.